Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States?

Genetics in Medicine

Volumn 17, Issue 11, 2015, Pages 897-900

  Palomaki, Glenn E ^a   Ashwood, Edward R ^b   Best, Robert G ^c   Lambert Messerlian, Geralyn ^a   Knight, George J ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE GREENVILLE   (United States)

Author keywords

Cell free DNA; Down syndrome; next generation sequencing; screening

Indexed keywords

DNA;

ADULT; ANEUPLOIDY; ARTICLE; CLINICAL LABORATORY; DNA SCREENING; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL PLASMA; NEXT GENERATION SEQUENCING; PREGNANT WOMAN; SECOND TRIMESTER PREGNANCY; UNITED STATES; BLOOD; GENETIC SCREENING; HEALTH SURVEY; HIGH THROUGHPUT SEQUENCING; MASS SCREENING; MIDDLE AGED; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; REPRODUCIBILITY; STANDARDS;

ADULT; ANEUPLOIDY; DNA; FEMALE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MASS SCREENING; MIDDLE AGED; PREGNANCY; PRENATAL DIAGNOSIS; PUBLIC HEALTH SURVEILLANCE; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 84947939390     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.39     Document Type: Article

References (12)

1. ACOG. Committee Opinion No. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-1534.
2. Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE. Screening for down syndrome in the United States: results of surveys in 2011 and 2012. Arch Pathol Lab Med 2013;137:921-926.
3. ACOG. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007;110:1459-1467.
4. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-920.
5. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013;33:542-546.
6. Taylor JB, Chock VY, Hudgins L. NIPT in a clinical setting: an analysis of uptake in the first months of clinical availability. J Genet Couns 2014;23:72-78.
7. Vahanian SA, Baraa Allaf M, Yeh C, Chavez MR, Kinzler WL, Vintzileos AM. Patient acceptance of non-invasive testing for fetal aneuploidy via cell-free fetal DNA. J Matern Fetal Neonatal Med 2014;27:106-109.
8. O'Brien BM, Kloza EM, Halliday JV, Lambert-Messerlian GM, Palomaki GE. Maternal plasma DNA testing: experience of women counseled at a prenatal diagnosis center. Genet Test Mol Biomarkers 2014;18:665-669.
9. Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open 2014;4:e005922.
10. Morris S, Karlsen S, Chung N, Hill M, Chitty LS. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One 2014;9:e93559.
11. Beulen L, Grutters JP, Faas BH, Feenstra I, van Vugt JM, Bekker MN. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Eur J Obstet Gynecol Reprod Biol 2014;182:53-61.
12. Ayres AC, Whitty JA, Ellwood DA. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol 2014;54:412-417.